Skip to Content

Altretamine Disease Interactions

There are 3 disease interactions with altretamine:

Major

Altretamine (Includes altretamine) ↔ myelosuppression

Severe Potential Hazard, Moderate plausibility. Applies to: Bone Marrow Depression/Low Blood Counts, Bleeding

The use of altretamine is contraindicated in patients with severe bone marrow suppression. Altretamine induces mild to moderate dose-related myelosuppression. If white blood cell counts fall below 2000/mm3 and/or platelet counts fall below 75,000/mm3 during altretamine therapy, subsequent doses should be withheld at least 14 days and altretamine restarted at 200 mg/m2/day. Clinical monitoring of hematopoietic function is recommended prior to each course of altretamine and the dose should be adjusted as clinically indicated.

References

  1. "Product Information. Hexalen Capsules (altretamine)." US Bioscience, West Conshohoken, PA.
Major

Altretamine (Includes altretamine) ↔ neurologic dysfunction

Severe Potential Hazard, High plausibility. Applies to: Neurologic Disorder

The use of altretamine is contraindicated in patients with severe neurological impairment. Peripheral neuropathy as well as central nervous system symptoms of ataxia, vertigo, mood disorders, and disorders of consciousness has been noted during administration of altretamine. However, altretamine has been administered safely to patients with cisplatin-associated neuropathy and to patients administered other alkylating agents. Clinical monitoring of neurologic function should be performed prior to the initiation of each course of therapy and the dose adjusted as clinically indicated in these patients.

References

  1. "Product Information. Hexalen Capsules (altretamine)." US Bioscience, West Conshohoken, PA.
Moderate

Altretamine (Includes altretamine) ↔ hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Altretamine is well-absorbed following oral administration in humans, but undergoes rapid and extensive demethylation in the liver, producing variation in altretamine plasma levels. Patients with liver disease may be at higher risk for adverse effects from altretamine. Caution is recommended when using this drug in patients with hepatic impairment as the pharmacokinetics of altretamine has not been evaluated.

Altretamine drug interactions

There are 185 drug interactions with altretamine

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide